Targets › HLA-G
5 programs from 4 companies in 5 trials: 5 Phase 1; Oncology, Other; next expected readout Dec 2026.
[Isoform 1]: Non-classical major histocompatibility class Ib molecule involved in immune regulatory processes at the maternal-fetal interface. In complex with B2M/beta-2 microglobulin binds a limited repertoire of nonamer self-peptides derived from intracellular proteins including histones and ribosomal proteins. (UniProt, P17693)
Open in Phaseline: the race on HLA-G, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shine-On Biomedical | SOB100 HLA-G targeted exosome with anti-HLA-G VHH nanobody | HLA-G | Phase 1 | Healthy Subjects | Dec 2026 |
| Tizona Therapeutics | TTX-080 HLA-G antagonist | HLA-G | Phase 1 | Cancer | Jun 2027 |
| Ever Supreme Bio Technology | HLA-G-CAR.BiTE allogeneic γδ T cells HLA-G-targeted CAR (chimeric antigen receptor) BiTE (bispecific T cell engager) allogeneic | HLA-G | Phase 1 | Solid Tumor | Jun 2027 |
| Shine-On Biomedical | SOA101 Nanobody-based trispecific antibody T cell engager targeting PD-L1/HLA-G/CD3 | CD274, HLA-G, CD3E | Phase 1 | Solid Tumors | Feb 2028 |
| Cancer Research UK | UCB4594 anti-HLA-G monoclonal antibody | HLA-G | Phase 1 | Advanced Solid Tumours | Nov 2029 |
Solid Tumors (1) Healthy Subjects (1) Advanced Solid Tumours (1) Cancer (1) Solid Tumor (1)
small molecule (3), mixed (1), other (1)
Shine-On Biomedical (2) Cancer Research UK (1) Tizona Therapeutics (1) Ever Supreme Bio Technology (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.